Page 58 - 南京医科大学学报自然科学版
P. 58
第43卷第12期
·1674 · 南 京 医 科 大 学 学 报 2023年12月
zumab for first⁃line treatment of metastatic nonsquamous [22] JOHNSON D B,BALKO J M,COMPTON M L,et al. Ful⁃
NSCLC[J]. N Engl J Med,2018,378(24):2288-301 minant myocarditis with combination immune checkpoint
[11] PAZ⁃ARES L,VICENTE D,TAFRESHI A,et al. A ran⁃ blockade[J]. N Engl J Med,2016,375(18):1749-1755
domized,placebo⁃controlled trial of pembrolizumab plus [23]RUBIO⁃INFANTE N,RAMÍREZ⁃FLORES Y A,CASTIL⁃
chemotherapy in patients with metastatic squamous LO E C,et al. A systematic review of the mechanisms in⁃
NSCLC:protocol⁃specified final analysis of KEYNOTE⁃ volved in immune checkpoint inhibitors cardiotoxicity
407[J]. J Thorac Oncol,2020,15:1657-1669 and challenges to improve clinical safety[J]. Front Cell
[12] HARATANI K,HAYASHI H,CHIBA Y,et al. Associa⁃ Dev Biol,2022,10:851032
tion of immune⁃related adverse events with nivolumab effi⁃ [24] WANG R,SHI M,JI M,et al. Real world experience with
cacy in non ⁃ small ⁃ cell lung cancer[J]. JAMA Oncol, camrelizumab in patients with advanced non ⁃ small cell
2018,4(3):374-378 lung cancer:a prospective multicenter cohort study(NO⁃
[13] SOCINSKI M A,JOTTE R M,CAPPUZZO F,et al. Asso⁃ AH⁃LC⁃101)[J]. Transl Lung Cancer Res,2023,12(4):
ciation of immune⁃related adverse events with efficacy of 786-796
atezolizumab in patients with non⁃small cell lung cancer: [25] YIN L,LIU K C,LV W F,et al. Predicting outcome in
pooled analyses of the phase 3 IMpower130,IMpower132, combination treatment of TACE and camrelizumab for ad⁃
and IMpower150 randomized clinical trials[J]. JAMA On⁃ vanced hepatocellular carcinoma:tumor hypervascularity
col,2023,9(4):527-535 and reactive cutaneous capillary endothelial proliferation
[14] 中国临床肿瘤学会指南工作委员. CSCO免疫检查点抑 [J]. Drug Des Devel Ther,2022,16:3421-3429
制剂相关的毒性管理指南2023[M]. 北京:人民卫生出 [26] WANG F,QIN S,SUN X,et al. Reactive cutaneous capil⁃
版社,2023:1-192 lary endothelial proliferation in advanced hepatocellular
[15] BRAHMER J R,LACCHETTI C,SCHNEIDER B J,et al. carcinoma patients treated with camrelizumab:data de⁃
National comprehensive cancer network. management of rived from a multicenter phase 2 trial[J]. J Hematol On⁃
immune⁃related adverse events in patients treated with im⁃ col,2020,13(1):47
mune checkpoint inhibitor therapy:American society of [27] OKIYAMA N,TANAKA R. Immune ⁃ related adverse
clinical oncology clinical practice guideline[J]. J Clin events in various organs caused by immune checkpoint in⁃
Oncol,2018,36(17):1714-1768 hibitors[J]. Allergol Int,2022,71(2):169-178
[16] THOMPSON J A. New NCCN guidelines:recognition and [28] MAYOUX M,ROLLER A,PULKO V,et al. Dendritic
management of immunotherapy⁃related toxicity[J]. J Natl cells dictate responses to PD⁃L1 blockade cancer immu⁃
Compr Canc Netw,2018,16(5S):594-596 notherapy[J]. Sci Transl Med,2020,12(534):7431
[17] COUZIN ⁃ FRANKEL J. Breakthrough of the year 2013. [29] YEARLEY JH,GIBSON C,YU N,ET al. PD⁃L2 expres⁃
Cancer immunotherapy[J]. Science,2013,342(6165): sion in human tumors:relevance to anti⁃PD⁃1 therapy in
1432-1433 cancer[J]. Clin Cancer Res,2017,23(12):3158-3167
[18] BAJWA R,CHEEMA A,KHAN T,et al. Adverse effects [30] KICHENADASSE G,MINERS J O,MANGONI A A,et
of immune checkpoint inhibitors(programmed death⁃1 in⁃ al. Multiorgan immune ⁃ related adverse events during
hibitors and cytotoxic T⁃lymphocyte⁃associated protein⁃4 treatment with atezolizumab[J]. J Natl Compr Canc Netw,
inhibitors):results of a retrospective study[J]. J Clin 2020,18(9):1191-1199
Med Res,2019,11(4):225-236 [31] SHANKAR B,ZHANG J,NAQASH A R,et al. Multisys⁃
[19] KUMAR P,SAINI S,PRABHAKAR B S. Cancer immuno⁃ tem immune ⁃ related adverse events associated with im⁃
therapy with check point inhibitor can cause autoimmune mune checkpoint inhibitors for treatment of non ⁃ small
adverse events due to loss of Treg homeostasis[J]. Semin cell lung cancer[J]. JAMA Oncol,2020,6(12):1952-
Cancer Biol,2020,64:29-35 1956
[20] TOPALIAN SL,HODI F S,BRAHMER J R,et al. Safety, [32] DAS S,JOHNSON D B. Immune⁃related adverse events
activity,and immune correlates of anti⁃PD⁃1 antibody in and anti⁃tumor efficacy of immune checkpoint inhibitors
cancer[J]. N Engl J Med,2012,366(26):2443-2454 [J]. J Immunother Cancer,2019,7(1):306
[21] VADDEPALLY R,DODDAMANI R,SODAVARAPU S, [33] RIEDER D,TRAJANOSKI Z. Checking immunotoxicity
et al. Review of immune⁃related adverse events(irAEs)in risks of checkpoint blockade[J]. Nat Cancer,2023,4
non ⁃ small ⁃ cell lung cancer(NSCLC)⁃ their incidence, (6):779⁃780
management,multiorgan irAEs,and rechallenge[J]. Bio⁃ [收稿日期] 2023-07-26
medicines,2022,10(4):790 (本文编辑:唐 震)